284 citations,
November 1999 in “Neurology” The article suggests managing interferon beta therapy side effects in MS with dose adjustments, medications, and patient education.
47 citations,
August 2016 in “American Journal Of Pathology” Fibroblast changes in systemic sclerosis may help understand disease severity and treatment.
37 citations,
May 2004 in “Multiple Sclerosis Journal” The article concludes that proper injection techniques and patient education can prevent serious skin reactions from multiple sclerosis medications.
18 citations,
March 2006 in “Expert Review of Neurotherapeutics” The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
12 citations,
March 2013 in “The American journal of dermatopathology/American journal of dermatopathology” Birt–Hogg–Dubé Syndrome requires genetic testing for accurate diagnosis due to its similarities with tuberous sclerosis.
6 citations,
March 2016 in “Multiple sclerosis and related disorders” Dimethyl-fumarate may cause temporary hair loss.
5 citations,
January 2016 in “European Journal of Dermatology” Suplatast tosilate successfully treated a woman's systemic sclerosis symptoms.
3 citations,
July 2021 in “International journal of environmental research and public health/International journal of environmental research and public health” Two patients developed complete hair loss after Alemtuzumab treatment for MS, with no regrowth after two years.
1 citations,
March 2022 in “Cureus” A woman with lupus and systemic sclerosis developed severe acne that didn't improve with treatment and died from pneumonia and septic shock.
September 2024 in “Journal of Ayurveda and Integrative Medicine” Ayurvedic treatments can improve symptoms and quality of life for systemic sclerosis patients.
A high fat lard diet may protect against skin fibrosis and affect hair growth.
July 2023 in “Journal of skin and stem cell” Interferon beta treatment in MS patients can cause skin reactions and increased hair loss.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Some multiple sclerosis treatments may trigger hair loss conditions like alopecia areata.
July 2021 in “British Journal of Dermatology” A woman with systemic sclerosis developed a unique scarring hair loss combining features of systemic sclerosis and frontal fibrosing alopecia.
January 2015 in “British journal of medicine and medical research” A woman with severe hair loss due to systemic sclerosis regrew her hair in 4 months using a combination of treatments.
Skin tumor cells in patients with tuberous sclerosis have higher levels of a protein called cathepsin B.
February 2009 in “Journal of The American Academy of Dermatology” Most patients with Tuberous sclerosis had neurological or skin issues, and over half had psychiatric problems.
253 citations,
April 2014 in “Drugs” Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
20 citations,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
5 citations,
August 2018 in “Neurology and Therapy” Hair thinning is a common but generally mild and reversible side effect of teriflunomide in multiple sclerosis patients.
1 citations,
March 2019 in “Journal of Interdisciplinary Medicine” A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.
45 citations,
July 2002 in “The Neurologist” A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.
36 citations,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
12 citations,
July 1957 in “Journal of Investigative Dermatology” Giving dihydrotachysterol to mother rats caused skin hardening and bone issues in their babies through milk.
4 citations,
May 2018 in “Journal of Neuro-Ophthalmology” New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
March 2015 in “Polish Journal of Public Health” Blood vessel patterns in skin diseases relate to certain blood markers in systemic sclerosis but not in psoriasis or psoriatic arthritis, and may indicate circulation issues in alopecia.
29 citations,
January 2016 in “CNS drugs” Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
16 citations,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
11 citations,
April 2018 in “The Journal of urology/The journal of urology” Post-void residual volume does not predict worsening urological symptoms in multiple sclerosis patients.
2 citations,
July 2022 in “Dermatology Reports” EPDS and MS might share an immune-related cause.